BACKGROUND AND OBJECTIVES: Some patients are not optimally treated by conventional in-center hemodialysis (HD) and are unable to perform home HD. We examined the effect of in-center thrice-weekly nocturnal HD (INHD) on patient outcomes. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: Patients who were not optimally treated on conventional HD were offered INHD. Thirty-nine patients' laboratory data and medication use were analyzed for the 12 mo before and after conversion to INHD until September 1, 2007. Quality of life on conventional HD and INHD was compared. RESULTS: After conversion to INHD, median values for phosphorus decreased from 5.9 to 3.7 mg/dl (P < 0.01), alkaline phosphatase level increased from 84 to 161 U/L (P < 0.01), and percentage reduction in urea increased from 74 to 89% (P < 0.01). The mean number of antihypertensive drugs prescribed declined from 2.0 to 1.5 (P < 0.05) during the course of INHD, and the mean daily dosage of phosphate binders declined from 6.2 to 4.9 at study end (P < 0.05). There was a significant reduction in erythropoietin-stimulating agent use of 1992 U/wk (P < 0.01). There was no significant change in median hemoglobin, iron saturation, corrected calcium, or parathyroid hormone levels. Overall, quality of life, sleep, intradialytic cramps, appetite, and energy level all improved significantly on INHD. CONCLUSIONS: INHD offers an effective form of HD for long-term dialysis patients who are unable to perform home HD.
BACKGROUND AND OBJECTIVES: Some patients are not optimally treated by conventional in-center hemodialysis (HD) and are unable to perform home HD. We examined the effect of in-center thrice-weekly nocturnal HD (INHD) on patient outcomes. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: Patients who were not optimally treated on conventional HD were offered INHD. Thirty-nine patients' laboratory data and medication use were analyzed for the 12 mo before and after conversion to INHD until September 1, 2007. Quality of life on conventional HD and INHD was compared. RESULTS: After conversion to INHD, median values for phosphorus decreased from 5.9 to 3.7 mg/dl (P < 0.01), alkaline phosphatase level increased from 84 to 161 U/L (P < 0.01), and percentage reduction in urea increased from 74 to 89% (P < 0.01). The mean number of antihypertensive drugs prescribed declined from 2.0 to 1.5 (P < 0.05) during the course of INHD, and the mean daily dosage of phosphate binders declined from 6.2 to 4.9 at study end (P < 0.05). There was a significant reduction in erythropoietin-stimulating agent use of 1992 U/wk (P < 0.01). There was no significant change in median hemoglobin, iron saturation, corrected calcium, or parathyroid hormone levels. Overall, quality of life, sleep, intradialytic cramps, appetite, and energy level all improved significantly on INHD. CONCLUSIONS: INHD offers an effective form of HD for long-term dialysis patients who are unable to perform home HD.
Authors: L L McPhatter; R S Lockridge; J Albert; H Anderson; V Craft; F M Jennings; M Spencer; A Swafford; T Barger; L Coffey Journal: Adv Ren Replace Ther Date: 1999-10
Authors: Christopher T Chan; John S Floras; Judith A Miller; Robert M A Richardson; Andreas Pierratos Journal: Kidney Int Date: 2002-06 Impact factor: 10.612
Authors: Christopher T Chan; Paula J Harvey; Peter Picton; Andreas Pierratos; Judith A Miller; John S Floras Journal: Hypertension Date: 2003-10-13 Impact factor: 10.190
Authors: Robert M Lindsay; Fayez Alhejaili; Gihad Nesrallah; Rosemary Leitch; Laurie Clement; A Paul Heidenheim; Claude Kortas Journal: Am J Kidney Dis Date: 2003-07 Impact factor: 8.860
Authors: Fayez Al-Hejaili; Claude Kortas; Rosemary Leitch; A Paul Heidenheim; Laurie Clement; Gihad Nesrallah; Robert M Lindsay Journal: J Am Soc Nephrol Date: 2003-09 Impact factor: 10.121
Authors: Allen R Nissenson; Suzanne K Swan; Jill S Lindberg; Steven D Soroka; Robert Beatey; Chao Wang; Nancy Picarello; Anna McDermott-Vitak; Bradley J Maroni Journal: Am J Kidney Dis Date: 2002-07 Impact factor: 8.860
Authors: Mark J Sarnak; Andrew S Levey; Anton C Schoolwerth; Josef Coresh; Bruce Culleton; L Lee Hamm; Peter A McCullough; Bertram L Kasiske; Ellie Kelepouris; Michael J Klag; Patrick Parfrey; Marc Pfeffer; Leopoldo Raij; David J Spinosa; Peter W Wilson Journal: Circulation Date: 2003-10-28 Impact factor: 29.690
Authors: Tammy L Sirich; Frank J-G Luo; Natalie S Plummer; Thomas H Hostetter; Timothy W Meyer Journal: Nephrol Dial Transplant Date: 2012-01-09 Impact factor: 5.992
Authors: Eduardo Lacson; Jianglin Xu; Rita S Suri; Gihad Nesrallah; Robert Lindsay; Amit X Garg; Keith Lester; Norma Ofsthun; Michael Lazarus; Raymond M Hakim Journal: J Am Soc Nephrol Date: 2012-02-23 Impact factor: 10.121
Authors: Tamryn K Law; Ron Wald; Marc Goldstein; Gauri R Karur; Ming-Yen Ng; Angela Y M Wang; Djeven P Deva; Anish Kirpalani; Rachel M Wald; Mercedeh Kiaii; Jonathon Leipsic; Kim A Connelly; Andrew T Yan Journal: J Nephrol Date: 2018-08-24 Impact factor: 3.902
Authors: Paweena Susantitaphong; Ioannis Koulouridis; Ethan M Balk; Nicolaos E Madias; Bertrand L Jaber Journal: Am J Kidney Dis Date: 2012-02-25 Impact factor: 8.860
Authors: Gauri R Karur; Ron Wald; Marc B Goldstein; Rachel Wald; Laura Jimenez-Juan; Mercedeh Kiaii; Jonathon Leipsic; Anish Kirpalani; Olugbenga Bello; Ashita Barthur; Ming-Yen Ng; Djeven P Deva; Andrew T Yan Journal: Nephrol Dial Transplant Date: 2018-06-01 Impact factor: 5.992
Authors: Baris U Agar; Alp Akonur; Ying-Cheng Lo; Alfred K Cheung; John K Leypoldt Journal: Clin J Am Soc Nephrol Date: 2011-10-27 Impact factor: 8.237
Authors: Eduardo Lacson; Weiling Wang; Keith Lester; Norma Ofsthun; J Michael Lazarus; Raymond M Hakim Journal: Clin J Am Soc Nephrol Date: 2009-12-03 Impact factor: 8.237